Trialsthymosin alpha-1ivfrecurrent implantation failureclinicaltrials.gov

Fakih IVF registers thymosin alpha-1 trial in recurrent implantation failure

The randomized, double-blind, placebo-controlled Phase 2/3 study tests the peptide as adjunctive immunomodulatory therapy after transfer of PGT-A tested embryos.

By Priya Raman · Science Reporter

Oct 15 08:00 ETSource: ClinicalTrials.gov

The wire

01ClinicalTrials.gov listing NCT07675980 is recruiting for a Phase 2/3 trial of thymosin alpha-1 in women with unexplained recurrent implantation failure undergoing IVF or ICSI, with a start date of 11 February 2026.
02Thymosin alpha-1 is better known as an immune peptide, and a controlled fertility trial would add human data in an indication currently driven by off-label immunomodulation.
03The registration gives no enrollment target, dose or endpoint details, and the sponsor is a single fertility center, so results will take years and may have limited generalizability.

From the source

Thymosin-α1 for Recurrent Implantation Failure
NCT07675980 · PHASE2/PHASE3 · RECRUITING · Sponsor: Fakih IVF Fertility Center · Conditions: Recurrent Implantation Faliure.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07675980